Colorectal Carcinoma

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

4 weeks ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial

Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher

4 weeks ago talkbio0Tagged Clinical Trials, Colorectal Carcinoma, Exelixis, regorafenib, STELLAR-303, surge, Tecentriq, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge

AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data

3 months ago talkbio0Tagged AACR, Cancer Research, Colorectal Carcinoma, Immunotherapy, Malignant neoplasm of breast, Marengo, oncology advancements

Cancer research, AACR 2025, Marengo Therapeutics, BriaCell, oncology advancements, colorectal cancer, breast cancer, immunotherapy

: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

3 months ago talkbio0Tagged Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Combined, first-line, United States Food and Drug Administration, Yervoy

United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

6 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.